Patient with Frederica's (QTcF) formulas (QTcF) ?450 msec;
Males with mean QTcF values of > 450 msec and females with QTcF values of > 470 msec following 3 ECGs conducted 5 minutes apart from each other; patients who are known to have congenital prolonged QT syndromes; or patients who are on medications known to cause prolonged QT intervals on ECG;
Corrected QT interval by Fredericia (QTcF) > 500 msec within 1 month before the first dose of study treatment:\r\n* Three electrocardiograms (ECGs) must be performed for eligibility determination. If the average of these three consecutive results for QTcF is =< 500 msec, the subject meets eligibility in this regard
QTcF > 460 msec on Screening electrocardiogram (ECG)
Participant has a QTcF interval > 450 msec (average of triplicate determinations) by central read.
Medical history of uncontrolled but clinically significant abnormal cardiac conduction abnormalities at electrocardiogram (ECG), any history or evidence of long QT syndrome or QTcF interval >450 msec for males and ?470 msec for females (according to Fridericia's correction) at screening
QTcF <500 msec
Fridericia's correction formula (QTcF) > 500 msec within 1 month before the first dose of study treatment:\r\n* Three electrocardiography (ECG)s must be performed for eligibility determination; if the average of these three consecutive results for QTcF is =< 500 msec, the subject meets eligibility in this regard
Evidence of currently uncontrolled cardiovascular conditions as listed in the protocol; acute myocardial infarction with 6 months before starting study drug; baseline QT interval (QTcF) greater than (>) 450 milliseconds (msec) (males) or > 475 msec (females); or abnormalities on baseline 12-lead electrocardiogram (ECG) that are considered clinically significant per investigator.
Patients with mean QTcF values of > 470 msec (in females) or > 450 msec (in males) following 3 ECGs conducted 5 minutes apart from each other; patients who are known to have congenital prolonged QT syndromes; or patients who are on medications known to cause prolonged QT intervals on ECG.
QTcF >450 milliseconds (msec) or QTcF >480 msec for subjects with bundle branch block
Interval from the Q wave on the ECG to point T using Fredericia's formula (QTcF) > 500 millisecond (msec)
QT interval adjusted according to Fredericia (QTcF) > 480 msec on screening electrocardiogram (ECG)
Significant abnormalities on ECG at screening. QTcF >450 msec for males or >470 msec for females at screening
Subjects with a QTcF interval of >470 msec; if the Screening ECG QTcF interval is >470 msec, it may be repeated, and if repeat <470 msec, the subject may be enrolled.
QTcF interval < 450 msec and mean resting heart rate 50-90 bpm
A baseline ECG QTcF > 470 msec
QTcF > 470 msec on the screening ECG
12 lead ECG with QtcF interval ? 470 msec
Screening QTcF >450 msec or current medication known to prolong QT
QTcF prolongation (defined as a QTcF > 450 msec)
QTcF >450 msec (males) or >470 msec (females).
On screening, any of the following cardiac parameters: bradycardia (heart rate < 50 at rest), tachycardia (heart rate > 90 at rest), PR interval > 220 msec, QRS interval >109 msec, or QTcF >450 msec.
At Screening QTcF ?450 msec for males and ?470 msec for females.
QTcF > 480 msec
Screening electrocardiogram (ECG) with a QTcF > 450 millisecond (msec)
QTcB ? 480 msec
QTcF >500 msec (males or females)
Mean QTcF ?450 msec (for males) or ?470 msec (for females) at Screening
Baseline mean QTcF ? 450 msec (for males) or ? 470 msec (for females) at Screening.
Predose mean QTc? 450 msec or QTcF ? 450 msec.
Mean QTcF interval > 450 msec at screening.
QTcF > 470 msec on the screening ECG
Subject with a QTcF of > 450 msec in male subjects and > 470 msec in female subjects on the screening 12 lead ECG.
Patients with baseline QTcF ? 480 msec
QTcF ? 450 msec for males or 470 msec for females.
Screening and Baseline QTcF (Fridericia's) less than 470 msec
Patient has clinically significant resting bradycardia (heart rate < 50 at rest), tachycardia (heart rate > 90 at rest), PR interval > 220 msec, QRS interval > 109 msec, or QTcF > 450 msec.
QTcF interval on electrocardiogram (ECG) at screening > 450 msec for males or > 460 for females;
The patient has QTcF interval greater than 450 msec, has a known history of QTcF prolongation, is taking medications known to prolong QTcF, or has a history of torsade de pointes.
Clinically relevant findings in the ECG such as a second- or third-degree AV block, prolongation of the QRS complex over 120 msec or of the QTcF-interval over 450 msec
Cardiovascular baseline corrected QT by Fridericia's (QTcF) > 450 msec (male) or QTcF > 470 msec (female) will exclude patients from entry on study
QTcF interval > 450 msec (males) or > 470 msec (females)
Pretreatment QTcF interval >470 msec (females) or >450 msec (males)
A baseline ECG QTcF > 470 msec
At Screening, QTcF >450 msec for males; QTcF >470 msec for females
QTcF interval < 450 msec and mean resting heart rate 50-90 bpm
Friderichia corrected QT interval (QTcF) >450 milliseconds (msec) (men) or >475 msec (women) on a 12-lead electrocardiogram (ECG) during the Screening period.
Prolongation of QTcF interval to >480 milliseconds (msec)
Subject has QTcF interval > 450 msec (average of triplicate determinations based on central reading).
